Skip to main content

Table 4. Univariate analyses of patients with or without 30% pain relief by mirogabalin

From: Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study

Variables< 30% pain relief
(n= 50)
≥ 30% pain relief
(n= 113)
pvalue
Age (years)72.9 ± 11.9 (45–88)71.3 ± 13.0 (30–94)0.46a
Sex, female/male30/2082/310.11b
Diagnosis  0.75b
 LCS3583
 CSM1117
 LDH27
 CTS26
 Others01
BMI (kg/m2)22.7 ± 4.2 (18–33)23.0 ± 3.8 (19–31)0.79a
DM4110.72b
NeP score (points)7.4 ± 2.1 (6–12)6.6 ± 1.4 (6–12)0.0047a
Primary doze (mg)3.1 ± 1.5 (5–10)3.1 ± 1.1 (5–10)0.97a
Max dose (mg)6.6 ± 3.8 (5–30)6.4 ± 3.8 (5–30)0.76a
Adverse events24 (48%)42 (37.2%)0.13b
 Somnolence17 (34%)27 (23.9%) 
 Dizziness6 (12%)10 (8.8%)
 Edema2 (4%)5 (4.4%)
 Weight gain1 (2%)0 (0%)
  1. Data are expressed as the mean ± standard deviation (range) or n (%).
  2. LCS lumbar canal stenosis, CSM cervical spondylotic myelopathy, LDH lumbar disc herniation, CTS carpal tunnel syndrome, BMI body mass index, DM diabetes mellitus, NeP neuropathic pain
  3. a Student’s t-test
  4. b Chi-squared test